Pharming Group N.V. (PHARM) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 148 PAGES: 36

More Info
									        Pharming Group N.V. (PHARM) - Financial and Strategic SWOT Analysis
                                     Review
        Reference Code: GDME7257FSA                                                                                           Publication Date: JUN 2013

          Darwinweg 24                                       Phone              +31 71 5247400                  Revenue          10.61 (million EUR)
          Leiden, Zuid-Holland                               Fax                +31 71 5247445                  Net Profit       -24.09 (million EUR)
          2333                                               Website            www.pharming.com                Employees        61
                                                                                PHARM            [Euronext
          The Netherlands                                    Exchange           Amsterdam            Stock      Industry         Medical Equipment
                                                                                Exchange]

       Company Overview
       Pharming Group N.V. (Pharming) is a biotechnology company. It develops, manufactures and commercializes human therapeutic
       proteins and nutritional products for the treatment of genetic diseases; ageing disorders; surgical and traumatic bleeding. The
       company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for the
       treatment of angioedema attacks in patients with hereditary angioedema (HAE). It’s product pipeline consists of Recombinant
       human C1 inhibitor (rhC1INH), Recombinant human factor VIII (rhFactor VIII) and Recombinant human lactoferrin (hLF). The
       company has manufacturing facilities in the Netherlands and the US.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Pharming Group N.V., SWOT Analysis
         Sijmen De Vries                     Chief Executive Officer                  Strengths                              Weaknesses
         Rienk Pijpstra                      Chief Medical Officer
                                                                                      Commercial Agreements                  Lack of Capital Resources
         Bruno M. Giannetti Ph.d.            Chief Operating Officer
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Proprietary Transgenic                 History of Net Losses
        Research, GlobalData                                                          production technology

       Share Data
         Pharming Group N.V.                                                          Opportunities                          Threats

        Share Price (EUR) as on 04-Jun-                                  0.08         Strong Pipeline Products               Stringent Government
        2013                                                                                                                 Regulations
                                                                                      Growing Aged Population
        EPS (EUR)                                                         NA
                                                                                                                             Changing Diagnostic Market
        Market Cap (million EUR)                                           11                                                Conditions
        Enterprise Value (million EUR)                                      8
        Shares Outstanding (million)                                     132         Source: Annual Report, Company Website, Primary and Secondary Research,
       Source: Annual Report, Company Website, Primary and Secondary                 GlobalData
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 16, 2013         Pharming Reports Q1 2013 Results
                                                                                      Mar 07, 2013         Pharming Reports Preliminary 2012 Results
                                                                                      Aug 23, 2012         Pharming Reports Revenue Of €1.8m In H1
                                                                                                           2012
                                                                                      Aug 02, 2012         Pharming Announces Restructuring Plan
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Pharming Group N.V. (PHARM) - Financial and Strategic SWOT                                                                      Reference Code: GDME7257FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 4
       Pharming Group N.V. - Key Facts ...................................................................................................................................................... 4
       Pharming Group N.V. - Key Employees ............................................................................................................................................. 5
       Pharming Group N.V. - Key Employee Biographies ........................................................................................................................... 6
       Pharming Group N.V. - Major Products and Services ........................................................................................................................ 7
       Pharming Group N.V. - Pharmaceutical Pipeline Products Data ........................................................................................................ 8
          Pharming Group N.V., Pipeline Products by Therapy Area ............................................................................................................ 8
          Pharming Group N.V., Pipeline Products by Development Phase .................................................................................................. 9
       Pharming Group N.V. - History ......................................................................................................................................................... 12
       Pharming Group N.V. - Company Statement ................................................................................................................................... 15
       Pharming Group N.V. - Locations And Subsidiaries ......................................................................................................................... 17
          Head Office ................................................................................................................................................................................... 17
          Other Locations & Subsidiaries ..................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       Pharming Group N.V. - Business Description................................................................................................................................... 18
       Pharming Group N.V. - Corporate Strategy ...................................................................................................................................... 19
       Pharming Group N.V. - SWOT Analysis ........................................................................................................................................... 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Pharming Group N.V. - Strengths ................................................................................................................................................. 20
             Strength - Commercial Agreements .......................................................................................................................................... 20
             Strength - Proprietary Transgenic production technology ......................................................................................................... 20
             Strength - Lead Product Candidate. .......................................................................................................................................... 20
          Pharming Group N.V. - Weaknesses ............................................................................................................................................ 21
             Weakness - Lack of Capital Resources..................................................................................................................................... 21
             Weakness - History of Net Losses ............................................................................................................................................ 21
          Pharming Group N.V. - Opportunities ........................................................................................................................................... 21
             Opportunity - Strong Pipeline Products ..................................................................................................................................... 21
             Opportunity - Growing Aged Population .................................................................................................................................... 21
             Opportunity - Strategic Divestitures ......................
								
To top